home / stock / alny / alny quote
Last: | $143.71 |
---|---|
Change Percent: | 0.56% |
Open: | $143 |
Close: | $143.71 |
High: | $145.79 |
Low: | $141.975 |
Volume: | 489,263 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$143.71 | $143 | $143.71 | $145.79 | $141.975 | 489,263 | 04-25-2024 |
$143.8 | $146.6 | $143.8 | $147.486 | $143.52 | 388,114 | 04-24-2024 |
$146.07 | $147.35 | $146.07 | $150.27 | $145.04 | 542,714 | 04-23-2024 |
$145.79 | $145.21 | $145.79 | $147.9 | $143.6911 | 399,984 | 04-22-2024 |
$144.41 | $144.72 | $144.41 | $146.92 | $143.5 | 703,168 | 04-19-2024 |
$145.16 | $145 | $145.16 | $146.47 | $144.23 | 398,914 | 04-18-2024 |
$145.32 | $146.7 | $145.32 | $147.49 | $145.19 | 601,282 | 04-17-2024 |
$146.72 | $146.37 | $146.72 | $148.44 | $146.01 | 352,430 | 04-16-2024 |
$147.7 | $148.62 | $147.7 | $150.37 | $146.73 | 498,939 | 04-15-2024 |
$148.5 | $151.8 | $148.5 | $151.8 | $148.28 | 428,052 | 04-12-2024 |
$152.09 | $154.02 | $152.09 | $154.02 | $149.93 | 473,419 | 04-11-2024 |
$152.41 | $154.89 | $152.41 | $154.955 | $151.91 | 571,403 | 04-10-2024 |
$155.9 | $157.26 | $155.9 | $159.34 | $154.89 | 595,961 | 04-09-2024 |
$156.04 | $154.63 | $156.04 | $157.96 | $153.25 | 738,226 | 04-08-2024 |
$153.56 | $150.15 | $153.56 | $154 | $149.4079 | 351,493 | 04-05-2024 |
$151.48 | $151 | $151.48 | $154.38 | $150.8 | 531,883 | 04-04-2024 |
$150.83 | $150.19 | $150.83 | $151.27 | $149.25 | 315,208 | 04-03-2024 |
$151.04 | $151.89 | $151.04 | $152.27 | $150.67 | 445,840 | 04-02-2024 |
$153.33 | $148.57 | $153.33 | $154.21 | $147.58 | 523,250 | 04-01-2024 |
$149.45 | $154.48 | $149.45 | $154.5 | $149.32 | 666,592 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Management will provide an update on the C...
On Sunday, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) presented results from the KARDIA-2 Phase 2 study, which evaluated the efficacy and...
– Study Met Primary Endpoint Demonstrating Clinically Significant Additive Reductions in Ambulatory Systolic Blood Pressure of Up to 12.1 mmHg Across Three Independent Study Cohorts at Month 3 – – A Single Dose of Zilebesiran Resulted in Clinically Significant Additiv...